Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
2 reports, 1 independent
Updated Sep 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Atrium
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
- FDA
Related events
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Canadian investors can access U.S. companies, including Bristol-Myers Squibb, via Canadian Deposit Receipts (CDRs).
- The FDA requested additional clinical data from Unicycive Therapeutics.